CareDx (CDNA)

CareDx is best known for non-invasive testing services used in transplant surveillance. Its commercial portfolio includes AlloSure Kidney, which measures donor-derived cell-free DNA for kidney transplant patients, and AlloMap Heart, a gene-expression profiling test used in heart transplant management. The company also offers AlloSure Heart and AlloSure Lung, extending its donor-derived cell-free DNA approach to heart and lung transplant recipients. These tests are designed to provide information that may help physicians detect potential signs of injury or rejection without relying solely on invasive procedures such as biopsies.

Most of CareDx’s revenue comes from testing services, and the United States is its primary market. The company also provides digital solutions and patient-management tools intended to improve coordination among transplant centers, physicians, caregivers, and patients. Its position is distinctive because transplant medicine requires long-term monitoring, specialized clinical workflows, and highly sensitive diagnostics. By concentrating on this niche, CareDx serves a market where timely and accurate information can be critical to protecting scarce donor organs and supporting patient outcomes. The company competes within the broader molecular diagnostics and precision medicine industry, but its brand and product development are closely tied to transplant care.